🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced today

Find Clinical Trials for Your Rare Disease

10592+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Showing 20 of 10592 recruiting trials

Phase 2RecruitingNCT06192160

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

👨‍⚕️ Radojka Savic, PharmD, PhD, University of California📍 28 sites📅 Started Mar 2025View details ↗
Phase 2, PHASE3RecruitingNCT06855810

Newly-diagnosed Pediatric T-cell ALL Protocol

👨‍⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06627270

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

👨‍⚕️ Natalie Silver, MD, Case Comprehensive Cancer Center, Cleveland Clinic Foundation📍 1 site📅 Started Mar 2025View details ↗
RecruitingNCT06784167

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

👨‍⚕️ Amrita Desai, OHSU Knight Cancer Institute📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT07412314

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

👨‍⚕️ Yuan Taize, private hospital📍 2 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT07246668

A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

🏥 Yonsei University📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT06773871

Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions

🏥 Rigshospitalet, Denmark📍 2 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT07046806

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

👨‍⚕️ Henry Li, MD📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT06374238

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

👨‍⚕️ Charles Jonassaint, PhD, University of Pittsburgh📍 14 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06730126

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

👨‍⚕️ V. Koneti Rao, M.D., National Institute of Allergy and Infectious Diseases (NIAID)📍 3 sites📅 Started Mar 2025View details ↗
NARecruitingNCT06806163

Machine-Learning Prediction and Reducing Overdoses With EHR Nudges

👨‍⚕️ Walid F Gellad, MD, MPH, University of Pittsburgh Center for Pharmaceutical Policy and Prescribing📍 1 site📅 Started Mar 2025View details ↗
RecruitingNCT06292598

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

👨‍⚕️ Catherine Dunyach-Remy, CHU de Nimes📍 2 sites📅 Started Mar 2025View details ↗
EARLY_Phase 1Enrolling by InvitationNCT06888661

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

🏥 Guangzhou Jiayin Biotech Ltd📍 2 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06326190

177Lu-DOTATATE for Recurrent Meningioma

👨‍⚕️ Prof. Nathalie Albert, EORTC Study Coordinator📍 12 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

👨‍⚕️ Jacob Garcia, MD, Umoja Biopharma📍 8 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06698822

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

👨‍⚕️ Julia Dai, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Mar 2025View details ↗
RecruitingNCT06973824

A Twenty-years' Experience in Pituitary Disease.

👨‍⚕️ Francesco Doglietto, Prof, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06925542

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

🏥 CRISPR Therapeutics📍 8 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06982729

Study of YK012 in Primary Membranous Nephropathy

👨‍⚕️ Minghui Zhao, M.D., Peking University First Hospital📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06875076

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

👨‍⚕️ Ma, The First Hospital of Jilin University📍 1 site📅 Started Mar 2025View details ↗
← PreviousPage 138 of 530Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →